Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide for fat loss, obesity & body recomposition.

Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established.

It had 1 arm (groups): Tirzepatide (experimental).

Tirzepatide self-administered once weekly by subcutaneous injection.

The registry classes the interventions as drug.

More on the Plan

This is especially concerning for older adults, as losing muscle mass can lead to weakness, falls, and disability.

Who Took Part

The registry lists 20 planned participants were the target.

It was open to people of any sex aged from 50 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Men and postmenopausal women aged 50 years or older. Body Mass Index (BMI) ≥30 kg/m². Willingness and ability to comply with all study procedures, including fasting requirements for certain visits. Able to provide informed consent and participate in all study assessments.

The full record lists 5 inclusion and 14 exclusion criteria; among the exclusions: body mass index (bmi) ≥ 40 kg/m²; moderate to severe gastroesophageal reflux disease based on patient history; inability to comply with the treatment protocol or to understand the consent form.

How the Study Was Run

Design: single-group and open-label.

Being open-label, the Tirzepatide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-04-01 with completion listed for 2027-04-01.

It ran at 1 site in United States.

Its stated primary purpose is other.

What Was Measured

Researchers chose this as the main measure: Appendicular lean muscle mass (time frame: 6 months). Muscle Strength (time frame: 6 months). Lower Extremity Functional Capacity (time frame: 6 months).

What This Means in Plain Language

Put simply, this is a phase 2 trial of Tirzepatide in 20 people with fat loss, obesity & body recomposition.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Fat loss, obesity & body recomposition research.